Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Welireg
03 Jun 2025 //
BIOSPACE
ARC-20: Casdatifan Combo Shows ~50% Response In Kidney Cancer
01 Jun 2025 //
BUSINESSWIRE
Arcus Retains Casdatifan, Announces $150M Stock Offering
18 Feb 2025 //
BUSINESSWIRE
Data Demonstrated Best-in-Class Potential for Casdatifan In Kidney Cancer
18 Feb 2025 //
BUSINESSWIRE